Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma

av De Santo, Carmela, Cheng, Paul, Beggs, Andrew, Egan, Sharon, Bessudo, Alberto, Mussai, Francis
I publikationen J Hematol Oncol (2018)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

av Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Wang, Bingxia, Sharma, Sunil, Bessudo, Alberto, Hui, Ai‐Min, Nemunaitis, John
I publikationen J Clin Pharmacol (2016)

Clinical Translation of Ferumoxytol-Based Vessel Size Imaging (VSI): Feasibility in a Phase I Oncology Clinical Trial Population

av Fredrickson, Jill, Serkova, Natalie J., Wyatt, Shelby K., Carano, Richard A. D., Pirzkall, Andrea, Rhee, Ina, Rosen, Lee S., Bessudo, Alberto, Weekes, Colin, de Crespigny, Alex
I publikationen Magn Reson Med (2016)

Denosumab for Treatment of Hypercalcemia of Malignancy

av Hu, Mimi I., Glezerman, Ilya G., Leboulleux, Sophie, Insogna, Karl, Gucalp, Rasim, Misiorowski, Waldemar, Yu, Bennett, Zorsky, Paul, Tosi, Diego, Bessudo, Alberto, Jaccard, Arnaud, Tonini, Giuseppe, Ying, Wendy, Braun, Ada, Jain, Rajul K.
Publicerad 2014

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type...

av Eng, Cathy, Bessudo, Alberto, Hart, Lowell L., Severtsev, Aleksey, Gladkov, Oleg, Müller, Lothar, Kopp, Mikhail V., Vladimirov, Vladimir, Langdon, Robert, Kotiv, Bogdan, Barni, Sandro, Hsu, Ching, Bolotin, Ellen, von Roemeling, Reinhard, Schwartz, Brian, Bendell, Johanna C.
I publikationen Int J Cancer (2016)

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanc...

av Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Bessudo, Alberto, Rasco, Drew W., Sharma, Sunil, O'Neil, Bert H., Wang, Bingxia, Liu, Guohui, Ke, Alice, Patel, Chirag, Rowland Yeo, Karen, Xia, Cindy, Zhang, Xiaoquan, Esseltine, Dixie‐Lee, Nemunaitis, John
I publikationen J Clin Pharmacol (2017)

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

av Berenson, James R., Cartmell, Alan, Bessudo, Alberto, Lyons, Roger M., Harb, Wael, Tzachanis, Dimitrios, Agajanian, Richy, Boccia, Ralph, Coleman, Morton, Moss, Robert A., Rifkin, Robert M., Patel, Priti, Dixon, Sandra, Ou, Ying, Anderl, Janet, Aggarwal, Sanjay, Berdeja, Jesus G.
I publikationen Blood (2016)

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

av Sharman, Jeff P., Forero-Torres, Andres, Costa, Luciano J., Flinn, Ian W., Inhorn, Lowell, Kelly, Kevin, Bessudo, Alberto, Fayad, Luis E., Kaminski, Mark S., Evens, Andrew M., Flowers, Christopher R., Sahin, Deniz, Mundt, Kirsten E., Sandmann, Thomas, Fingerle-Rowson, Günter, Vignal, Charlotte, Mobasher, Mehrdad, Zelenetz, Andrew D.
I publikationen Leuk Lymphoma (2018)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

av Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, van der Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert
I publikationen Oncologist (2019)